Illumina, Inc. (NASDAQ:ILMN) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Illumina, Inc.

In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, ...

Illumina said adding SomaLogic would support the company’s multiomics strategy and strengthen the value of its NovaSeq X ...

Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene ...

Illumina, Inc. will acquire SomaLogic for $350 million plus performance-based milestones. The acquisition advances Illumina's multiomics strategy, combining SomaLogic's proteomics technology with ...

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein ...

Illumina to acquire SomaLogic, a leader in data-driven proteomics technology, for $350 million: San Diego Tuesday, June 24, 2025, 12:00 Hrs [IST] Illumina, Inc., a global leader i ...

Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven ...

Illumina inked a deal with Standard BioTools to acquire SomaLogic for $350 million in cash. The maker of gene-sequencing equipment and services said Monday that the deal includes an additional payout ...

Illumina expects the addition of a high-margin revenue stream, although the deal is expected to close in 2026.

Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, ...

Illumina will acquire SomaLogic to expand in proteomics, adding new revenue streams and accelerating tech development in ...